A Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, Safety, Tolerability, and PK Study of an IV Form of TR-701 Free Acid and an Open-Label, Crossover Absolute BA Determination of a TR-701 FA Tablet in Normal Healthy Adults.

Trial Profile

A Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, Safety, Tolerability, and PK Study of an IV Form of TR-701 Free Acid and an Open-Label, Crossover Absolute BA Determination of a TR-701 FA Tablet in Normal Healthy Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 May 2016

At a glance

  • Drugs Tedizolid (Primary) ; Tedizolid (Primary)
  • Indications Gram-positive infections; Skin and soft tissue infections
  • Focus Adverse reactions
  • Acronyms IV/SAD/MAD
  • Sponsors Cubist Pharmaceuticals; Trius Therapeutics
  • Most Recent Events

    • 12 Sep 2010 Pharmacokinetic results presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 26 Jul 2010 Actual patient number is xx according to ClinicalTrials.gov.
    • 26 Jul 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top